Financhill
Sell
32

ARDX Quote, Financials, Valuation and Earnings

Last price:
$5.46
Seasonality move :
-14.07%
Day range:
$5.38 - $5.52
52-week range:
$4.32 - $9.33
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.86x
P/B ratio:
7.52x
Volume:
2.8M
Avg. volume:
3.4M
1-year change:
-31.88%
Market cap:
$1.3B
Revenue:
$333.6M
EPS (TTM):
-$0.16

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ARDX
Ardelyx
$111.2M -$0.00 72.66% -33.34% $10.75
BBIO
BridgeBio Pharma
$4M -$1.09 -78.03% -330% $53.50
ESPR
Esperion Therapeutics
$61.6M -$0.16 -60.09% -68.5% $6.63
INSM
Insmed
$102.4M -$1.16 19.4% -27.03% $95.66
RGEN
Repligen
$167.6M $0.41 6.61% 481.15% $194.07
UTHR
United Therapeutics
$734.7M $6.84 7.61% 6.87% $400.54
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ARDX
Ardelyx
$5.47 $10.75 $1.3B -- $0.00 0% 3.86x
BBIO
BridgeBio Pharma
$32.97 $53.50 $6.3B -- $0.00 0% 27.65x
ESPR
Esperion Therapeutics
$1.50 $6.63 $296.8M -- $0.00 0% 0.87x
INSM
Insmed
$76.53 $95.66 $13.9B -- $0.00 0% 34.51x
RGEN
Repligen
$150.62 $194.07 $8.4B 633.44x $0.00 0% 13.36x
UTHR
United Therapeutics
$307.24 $400.54 $13.8B 12.49x $0.00 0% 5.18x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ARDX
Ardelyx
46.54% 1.635 12.5% 3.95x
BBIO
BridgeBio Pharma
679.11% 1.994 32.94% 4.44x
ESPR
Esperion Therapeutics
-303.11% 3.463 67.84% 0.91x
INSM
Insmed
79.45% 6.110 8.91% 4.99x
RGEN
Repligen
-- 0.912 -- 8.43x
UTHR
United Therapeutics
4.45% 1.276 1.9% 4.80x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ARDX
Ardelyx
$97.9M $8.1M -15.08% -24.57% 9.07% $9.2M
BBIO
BridgeBio Pharma
$3.8M -$221.3M -108.74% -- -4019.3% -$198.6M
ESPR
Esperion Therapeutics
$43.5M -$4.4M -- -- -7.08% -$35M
INSM
Insmed
$78.3M -$245.2M -82.19% -41989.34% -205.36% -$202.8M
RGEN
Repligen
$38.8M -$33.3M -1.2% -1.29% -19.78% $42.2M
UTHR
United Therapeutics
$660M $363.7M 18.64% 20.21% 54.95% $254.5M

Ardelyx vs. Competitors

  • Which has Higher Returns ARDX or BBIO?

    BridgeBio Pharma has a net margin of 4% compared to Ardelyx's net margin of -4506.12%. Ardelyx's return on equity of -24.57% beat BridgeBio Pharma's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ARDX
    Ardelyx
    84.27% $0.02 $324.1M
    BBIO
    BridgeBio Pharma
    64.57% -$1.40 $263.8M
  • What do Analysts Say About ARDX or BBIO?

    Ardelyx has a consensus price target of $10.75, signalling upside risk potential of 96.53%. On the other hand BridgeBio Pharma has an analysts' consensus of $53.50 which suggests that it could grow by 62.27%. Given that Ardelyx has higher upside potential than BridgeBio Pharma, analysts believe Ardelyx is more attractive than BridgeBio Pharma.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARDX
    Ardelyx
    9 2 0
    BBIO
    BridgeBio Pharma
    9 3 0
  • Is ARDX or BBIO More Risky?

    Ardelyx has a beta of 0.873, which suggesting that the stock is 12.739% less volatile than S&P 500. In comparison BridgeBio Pharma has a beta of 1.069, suggesting its more volatile than the S&P 500 by 6.858%.

  • Which is a Better Dividend Stock ARDX or BBIO?

    Ardelyx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BridgeBio Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx pays -- of its earnings as a dividend. BridgeBio Pharma pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARDX or BBIO?

    Ardelyx quarterly revenues are $116.1M, which are larger than BridgeBio Pharma quarterly revenues of $5.9M. Ardelyx's net income of $4.6M is higher than BridgeBio Pharma's net income of -$265.1M. Notably, Ardelyx's price-to-earnings ratio is -- while BridgeBio Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx is 3.86x versus 27.65x for BridgeBio Pharma. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARDX
    Ardelyx
    3.86x -- $116.1M $4.6M
    BBIO
    BridgeBio Pharma
    27.65x -- $5.9M -$265.1M
  • Which has Higher Returns ARDX or ESPR?

    Esperion Therapeutics has a net margin of 4% compared to Ardelyx's net margin of -30.85%. Ardelyx's return on equity of -24.57% beat Esperion Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ARDX
    Ardelyx
    84.27% $0.02 $324.1M
    ESPR
    Esperion Therapeutics
    62.91% -$0.11 -$96.4M
  • What do Analysts Say About ARDX or ESPR?

    Ardelyx has a consensus price target of $10.75, signalling upside risk potential of 96.53%. On the other hand Esperion Therapeutics has an analysts' consensus of $6.63 which suggests that it could grow by 342.08%. Given that Esperion Therapeutics has higher upside potential than Ardelyx, analysts believe Esperion Therapeutics is more attractive than Ardelyx.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARDX
    Ardelyx
    9 2 0
    ESPR
    Esperion Therapeutics
    3 2 0
  • Is ARDX or ESPR More Risky?

    Ardelyx has a beta of 0.873, which suggesting that the stock is 12.739% less volatile than S&P 500. In comparison Esperion Therapeutics has a beta of 1.042, suggesting its more volatile than the S&P 500 by 4.237%.

  • Which is a Better Dividend Stock ARDX or ESPR?

    Ardelyx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Esperion Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx pays -- of its earnings as a dividend. Esperion Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARDX or ESPR?

    Ardelyx quarterly revenues are $116.1M, which are larger than Esperion Therapeutics quarterly revenues of $69.1M. Ardelyx's net income of $4.6M is higher than Esperion Therapeutics's net income of -$21.3M. Notably, Ardelyx's price-to-earnings ratio is -- while Esperion Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx is 3.86x versus 0.87x for Esperion Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARDX
    Ardelyx
    3.86x -- $116.1M $4.6M
    ESPR
    Esperion Therapeutics
    0.87x -- $69.1M -$21.3M
  • Which has Higher Returns ARDX or INSM?

    Insmed has a net margin of 4% compared to Ardelyx's net margin of -225.53%. Ardelyx's return on equity of -24.57% beat Insmed's return on equity of -41989.34%.

    Company Gross Margin Earnings Per Share Invested Capital
    ARDX
    Ardelyx
    84.27% $0.02 $324.1M
    INSM
    Insmed
    74.96% -$1.32 $1.4B
  • What do Analysts Say About ARDX or INSM?

    Ardelyx has a consensus price target of $10.75, signalling upside risk potential of 96.53%. On the other hand Insmed has an analysts' consensus of $95.66 which suggests that it could grow by 25%. Given that Ardelyx has higher upside potential than Insmed, analysts believe Ardelyx is more attractive than Insmed.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARDX
    Ardelyx
    9 2 0
    INSM
    Insmed
    12 0 0
  • Is ARDX or INSM More Risky?

    Ardelyx has a beta of 0.873, which suggesting that the stock is 12.739% less volatile than S&P 500. In comparison Insmed has a beta of 1.280, suggesting its more volatile than the S&P 500 by 27.99%.

  • Which is a Better Dividend Stock ARDX or INSM?

    Ardelyx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx pays -- of its earnings as a dividend. Insmed pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARDX or INSM?

    Ardelyx quarterly revenues are $116.1M, which are larger than Insmed quarterly revenues of $104.4M. Ardelyx's net income of $4.6M is higher than Insmed's net income of -$235.5M. Notably, Ardelyx's price-to-earnings ratio is -- while Insmed's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx is 3.86x versus 34.51x for Insmed. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARDX
    Ardelyx
    3.86x -- $116.1M $4.6M
    INSM
    Insmed
    34.51x -- $104.4M -$235.5M
  • Which has Higher Returns ARDX or RGEN?

    Repligen has a net margin of 4% compared to Ardelyx's net margin of -20.22%. Ardelyx's return on equity of -24.57% beat Repligen's return on equity of -1.29%.

    Company Gross Margin Earnings Per Share Invested Capital
    ARDX
    Ardelyx
    84.27% $0.02 $324.1M
    RGEN
    Repligen
    23.18% -$0.60 $407.4M
  • What do Analysts Say About ARDX or RGEN?

    Ardelyx has a consensus price target of $10.75, signalling upside risk potential of 96.53%. On the other hand Repligen has an analysts' consensus of $194.07 which suggests that it could grow by 28.85%. Given that Ardelyx has higher upside potential than Repligen, analysts believe Ardelyx is more attractive than Repligen.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARDX
    Ardelyx
    9 2 0
    RGEN
    Repligen
    9 5 0
  • Is ARDX or RGEN More Risky?

    Ardelyx has a beta of 0.873, which suggesting that the stock is 12.739% less volatile than S&P 500. In comparison Repligen has a beta of 0.950, suggesting its less volatile than the S&P 500 by 5.001%.

  • Which is a Better Dividend Stock ARDX or RGEN?

    Ardelyx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Repligen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx pays -- of its earnings as a dividend. Repligen pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARDX or RGEN?

    Ardelyx quarterly revenues are $116.1M, which are smaller than Repligen quarterly revenues of $167.5M. Ardelyx's net income of $4.6M is higher than Repligen's net income of -$33.9M. Notably, Ardelyx's price-to-earnings ratio is -- while Repligen's PE ratio is 633.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx is 3.86x versus 13.36x for Repligen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARDX
    Ardelyx
    3.86x -- $116.1M $4.6M
    RGEN
    Repligen
    13.36x 633.44x $167.5M -$33.9M
  • Which has Higher Returns ARDX or UTHR?

    United Therapeutics has a net margin of 4% compared to Ardelyx's net margin of 40.94%. Ardelyx's return on equity of -24.57% beat United Therapeutics's return on equity of 20.21%.

    Company Gross Margin Earnings Per Share Invested Capital
    ARDX
    Ardelyx
    84.27% $0.02 $324.1M
    UTHR
    United Therapeutics
    89.69% $6.19 $6.7B
  • What do Analysts Say About ARDX or UTHR?

    Ardelyx has a consensus price target of $10.75, signalling upside risk potential of 96.53%. On the other hand United Therapeutics has an analysts' consensus of $400.54 which suggests that it could grow by 30.37%. Given that Ardelyx has higher upside potential than United Therapeutics, analysts believe Ardelyx is more attractive than United Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARDX
    Ardelyx
    9 2 0
    UTHR
    United Therapeutics
    7 5 0
  • Is ARDX or UTHR More Risky?

    Ardelyx has a beta of 0.873, which suggesting that the stock is 12.739% less volatile than S&P 500. In comparison United Therapeutics has a beta of 0.638, suggesting its less volatile than the S&P 500 by 36.156%.

  • Which is a Better Dividend Stock ARDX or UTHR?

    Ardelyx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. United Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx pays -- of its earnings as a dividend. United Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARDX or UTHR?

    Ardelyx quarterly revenues are $116.1M, which are smaller than United Therapeutics quarterly revenues of $735.9M. Ardelyx's net income of $4.6M is lower than United Therapeutics's net income of $301.3M. Notably, Ardelyx's price-to-earnings ratio is -- while United Therapeutics's PE ratio is 12.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx is 3.86x versus 5.18x for United Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARDX
    Ardelyx
    3.86x -- $116.1M $4.6M
    UTHR
    United Therapeutics
    5.18x 12.49x $735.9M $301.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Qualcomm Stock: 5G Leader at a Bargain Price?
Qualcomm Stock: 5G Leader at a Bargain Price?

Chip giant QUALCOMM Incorporated (NASDAQ:QCOM) was the ultimate chip company…

What Is Buffett Buying and Selling Now?
What Is Buffett Buying and Selling Now?

In Q4 of last year, Warren Buffett made a few…

3 Safest Stocks to Buy Now
3 Safest Stocks to Buy Now

With the S&P 500 now in correction and stocks selling…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
59
GRRR alert for Mar 15

Gorilla Technology Group [GRRR] is up 29.72% over the past day.

Sell
49
SMTC alert for Mar 15

Semtech [SMTC] is up 21.28% over the past day.

Buy
62
PLPC alert for Mar 15

Preformed Line Products [PLPC] is up 17.38% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock